JAB-30300, P53 Y220C activator, received IND approval in the United States
JACUS Pharmaceuticals (1167.HK) announced that its independently developed P53 Y220C activator JAB-30300 has been approved for new drug clinical trial...
cancers
JACUS Pharmaceuticals (1167.HK) announced that its independently developed P53 Y220C activator JAB-30300 has been approved for new drug clinical trial...
